Biblio

Found 6 results
Filters: Author is Zhang, Li  [Clear All Filters]
2018
R. Aggarwal, Huang, J., Alumkal, J. J., Zhang, L., Feng, F. Y., Thomas, G. V., Weinstein, A. S., Friedl, V., Zhang, C., Witte, O. N., and , “Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study.”, 2018.
R. Raj Aggarwal, Lloyd, P., Huang, J., Beer, T. M., Zhang, L., Thomas, G. V., True, L. D., Alumkal, J. J., Friedl, V., Weinstein, A., and , “DNA repair mutations and treatment-emergent small cell neuroendocrine prostate cancer (t-SCNC) as hallmarks of distinct subgroups of metastatic castration resistant prostate cancer (mCRPC): Data from the West Coast Prostate Cancer Dream Team.”. American Society of Clinical Oncology, 2018.
2016
E. Jay Small, Aggarwal, R. Raj, Huang, J., Sokolov, A., Zhang, L., Alumkal, J. J., Youngren, J., Ryan, C. J., Foye, A., Reiter, R. Evan, and , “Clinical and genomic characterization of metastatic small cell/neuroendocrine prostate cancer (SCNC) and intermediate atypical prostate cancer (IAC): Results from the SU2C/PCF/AACRWest Coast Prostate Cancer Dream Team (WCDT).”. American Society of Clinical Oncology, 2016.
W. Kim, Ryan, C. J., Zhang, L., Youngren, J., Wilton, J., Alumkal, J. J., Beer, T. M., Baertsch, R., Stuart, J., Chi, K. N., and , “Dehydroepiandrosterone (DHEA) in metastatic castration-resistant prostate cancer (mCRPC): Preliminary results from the SU2C/PCF/AACR West Coast Dream Team (WCDT).”. American Society of Clinical Oncology, 2016.
W. Kim, Ryan, C. J., Zhang, L., Youngren, J., Wilton, J., Alumkal, J. J., Beer, T. M., Baertsch, R., Stuart, J., Chi, K. N., and , “Dehydroepiandrosterone in metastatic castration-resistant prostate cancer: Preliminary results from the SU2C-PCF West Coast Dream Team (WCDT).”. American Society of Clinical Oncology, 2016.
2015
E. Jay Small, Huang, J., Youngren, J., Sokolov, A., Aggarwal, R. Raj, Thomas, G., True, L. D., Zhang, L., Foye, A., Alumkal, J. J., and , “Characterization of neuroendocrine prostate cancer (NEPC) in patients with metastatic castration resistant prostate cancer (mCRPC) resistant to abiraterone (Abi) or enzalutamide (Enz): Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer ”. American Society of Clinical Oncology, 2015.